As of 3/17/16
7 a.m. – 8 a.m. | Check-in and Onsite Registration | ||||
8 a.m. – 8:10 a.m. | Welcome & Introductions Lisa H. Butterfield, PhD – University of Pittsburgh James Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health |
||||
Session I: Immunologic Monitoring Assay Standardization and Validation Co-Chairs: Magdalena Thurin, PhD – National Cancer Institute, National Institutes of Health Giuseppe V. Masucci, MD, PhD – Karolinska Institutet |
|||||
8:10 a.m. – 8:15 a.m. | Session I Introduction Magdalena Thurin, PhD – National Cancer Institute, National Institutes of Health |
||||
8:15 a.m. – 8:30 a.m. | Pre-Clinical Validation & Validation Process Alessandra Cesano, MD, PhD – NanoString Inc. |
||||
8:30 a.m. – 8:45 a.m. | TCR Sequencing Technology Platform Ilan Kirsch, MD – Adaptive Biotechnologies Corporation |
||||
8:45 a.m. – 9 a.m. | Blood Assays in Pre-Analytical Validation (Proficiency Panels & Harmonization) Sylvia Janetzki, MD – ZellNet Consulting, Inc. |
||||
9 a.m. – 9:15 a.m. | Regulatory Considerations for Diagnostic Devices in Cancer Immunotherapy Shyam Kalavar, MPH, CT(ASCP) – U.S. Food and Drug Administration |
||||
|
|
||||
|
Break | ||||
Session II: New Developments in Biomarker Assays and New Technologies Chair: Jianda Yuan, MD, PhD – Merck & Co., Inc. |
|||||
10 a.m. – 10:05 a.m. | Session II Introduction Jianda Yuan, MD, PhD – Merck & Co., Inc. |
||||
10:05 a.m. – 10:20 a.m. | Multispectral Imaging Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
||||
10:20 a.m. – 10:35 a.m. | Mutational Landscapes and Immunotherapy Efficacy Jianda Yuan, MD, PhD – Merck & Co., Inc. |
||||
10:35 a.m. – 10:50 a.m. | Defining New Metrics of Immune Competence by CyTOF Holden Maecker, PhD – Stanford University Medical Center |
||||
10:50 a.m. – 11:05 a.m. | Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-treated Melanoma Patients Cristina Maccalli, PhD – Sidra Medical and Research Center |
||||
11:05 a.m. – 11:35 a.m. | Panel Questions and Answers | ||||
11:35 a.m. – 12:35 p.m. | Break | ||||
Session III: Assessment of Immune Regulation and Modulation Systematically (High Throughput Approaches) Chair: David F. Stroncek, MD – National Cancer Institute, National Institutes of Health |
|||||
12:35 p.m. – 12:40 p.m. | Session III Introduction David F. Stroncek, MD – National Cancer Institute, National Institutes of Health |
||||
12:40 p.m. – 12:55 p.m. | Tumor Microenvironment Peter P. Lee, MD – City of Hope |
||||
12:55 p.m. – 1:10 p.m. | Monitoring Adoptive Cellular Therapies David F. Stroncek, MD – National Cancer Institute, National Institutes of Health |
||||
1:10 p.m. – 1:25 p.m. | Monitoring of Studies Barbara Seliger, MD, PhD – Martin Luther University Halle-Wittenberg |
||||
1:25 p.m. – 1:40 p.m. | Analysis of the Systemic Host Response Janet Siebert, MS – CytoAnalytics |
||||
1:40 p.m. – 2:10 p.m. | Panel Questions and Answers | ||||
2:10 p.m. – 2:25 p.m. | Break | ||||
Session IV: Prediction of Clinical Outcome Based on Baseline Measures Chair: Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai |
|||||
2:25 p.m. – 2:30 p.m. | Session IV Introduction Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai |
||||
2:30 p.m. – 2:45 p.m. | Tumor Microenvironment at a Genetic Level Samir N. Khleif, MD – Georgia Cancer Center |
||||
2:45 p.m. – 3 p.m. | Multiplex IHC Vaios Karanikas, PhD – Roche Innovation Center Zurich |
||||
3 p.m. – 3:15 p.m. | Multiplex/Blood Profiles Marcus O. Butler, MD – Princess Margaret Hospital/Ontario Cancer Institute |
||||
3:15 p.m. – 3:30 p.m. | Serology and IHC at the Tumor Site Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai |
||||
3:30 p.m. – 4 p.m. | Panel Questions and Answers | ||||
Session V: National Cancer Institute Perspectives on Biomarkers Chair: James Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health |
|||||
4 p.m. – 4:15 p.m. | Lessons Learned from the Peripheral Immunoscore Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health |
||||
4:15 p.m. – 4:30 p.m. | Extracellular Vesicles as Biomarkers of Immune Responses and Tumor Responses in Cancer Immunotherapy Jay A. Berzofsky, MD, PhD – National Cancer Institute, National Institutes of Health |
||||
4:30 p.m. – 4:45 p.m. | Panel Questions and Answers | ||||
4:45 p.m. – 5 p.m. | Closing Remarks James Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health |
Back to Immunotherapy Biomarkers 2016: Overcoming the Barriers General Information